Invanz and Malignant neoplasm progression - a phase IV clinical study of FDA data

Summary:

Malignant neoplasm progression is reported as a side effect among people who take Invanz (ertapenem sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lasix, and have Cholangiocarcinoma.

The phase IV clinical study analyzes which people have Malignant neoplasm progression when taking Invanz. It is created by eHealthMe based on reports of 3,924 people who have side effects when taking Invanz from the FDA, and is updated regularly.

What is Invanz?

Invanz has active ingredients of ertapenem sodium. It is often used in urinary tract infection. eHealthMe is studying from 3,961 Invanz users. Check the latest studies of Invanz.

What is Malignant neoplasm progression?

Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,516 drugs and 1,634 conditions by eHealthMe. Check the latest studies of Malignant neoplasm progression.

On Jul, 07, 2026

3,924 people reported to have side effects when taking Invanz.
Among them, 11 people (0.28%) have Malignant neoplasm progression.

Could Invanz cause Malignant neoplasm progression?

Among these 11 people:

How long have people been on Invanz when they have Malignant neoplasm progression? *

What is the gender of people who have Malignant neoplasm progression when taking Invanz? *

female: 80 %
male: 20 %

What is the age of people who have Malignant neoplasm progression when taking Invanz? *

What are other drugs people take besides Invanz? *

What are other side effects people have besides Malignant neoplasm progression? *

Abdominal Pain Upper: 3 people, 27.27%
Fatigue (feeling of tiredness): 3 people, 27.27%
Rashes (redness): 2 people, 18.18%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 2 people, 18.18%
Nausea (feeling of having an urge to vomit): 2 people, 18.18%
Neck Mass (mass in neck): 2 people, 18.18%
Oedema Peripheral (superficial swelling): 2 people, 18.18%
Metastases To Liver (cancer spreads to liver): 2 people, 18.18%
Memory Loss: 2 people, 18.18%
Local Swelling (swelling at the site of some application of substance or injury): 2 people, 18.18%

What are the existing conditions these people have? *

Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 2 people, 18.18%
Urticaria (rash of round, red welts on the skin that itch intensely): 1 person, 9.09%
Traumatic Injury Of The Bladder And Urethra: 1 person, 9.09%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 9.09%
Back Pain: 1 person, 9.09%
Breast Cancer Metastatic: 1 person, 9.09%
Cerebral Artery Stenosis (hardening of brain blood vessels): 1 person, 9.09%
Cervix Carcinoma (cancer of cervix): 1 person, 9.09%
Constipation: 1 person, 9.09%
Depression: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Invanz and have Malignant neoplasm progression?

- Check whether Malignant neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Invanz:

Invanz (3,961 reports)

Browse all side effects of Invanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,516 drugs)

Browse all the conditions that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,634 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ertapenem sodium (the active ingredients of Invanz) and Invanz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.